CME webinar: Intimate Partner Violence: Driving Forward Toward Solutions (recorded)
Sep. 2023Important Notices
Marlex Pharmaceuticals Inc. is recalling two lots of this drug because of a label mix-up. Bottles of Digoxin Tablets USP 0.125 mg are incorrectly labeled and contain Digoxin Tablets USP 0.25 mg. Bottles of Digoxin Tablets USP 0.25 mg are incorrectly labeled and contain Digoxin Tablets USP 0.125 mg. This drug is used for the treatment of mild to moderate heart failure. Read the full text of the voluntary Digoxin recall.
Recent Announcements
Medicaid Renewal
Starting in 2027, some Medicaid recipients (ages 19–-64) will have new requirements to keep their coverage.Aug. 2026Important Notices
Provider Directory Updates and Required Attestation
As you know, UPMC Health Plan requires all providers to verify their provider directory information at least every 90 days (quarterly).Aug. 2026Important Notices
Voluntary nationwide recall: Tyenne (Fresenius – August 2026)
Fresenius Kabi is recalling one lot, lot 16UI07, of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL) 20 mL vials. Tyenne is used for the treatment of certain arthritis conditions.Aug. 2026Pharmacy Updates